¤ OpenAccess: Bronze

This work has “Bronze” OA status. This means it is free to read on the publisher landing page, but without any identifiable license.

Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

Peter Schmid,Jonathan E. Rosenberg,Guru Sonpavde,Yohann Loriot,Ignacio Durán,Jae‐Lyun Lee,Nobuaki Matsubara,Christof Vulsteke,Daniel Castellano,Chunzhang Wu,Mary S. Campbell,Maria Matsangou,Daniel P. Petrylak

Medicine

Internal medicine

Hazard ratio

2021

Patients with advanced urothelial carcinoma have poor overall survival after platinum-containing chemotherapy and programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitor treatment.

Cite this:

Generate Citation

“Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma” is a paper by Peter Schmid Jonathan E. Rosenberg Guru Sonpavde Yohann Loriot Ignacio Durán Jae‐Lyun Lee Nobuaki Matsubara Christof Vulsteke Daniel Castellano Chunzhang Wu Mary S. Campbell Maria Matsangou Daniel P. Petrylak published in 2021. It has an Open Access status of “bronze”. You can read and download a PDF Full Text of this paper here.